注射用胰激肽原酶治疗糖尿病肾病高凝状态探讨.docVIP

KKME---专业医学搜索引擎/ 注射用胰激肽原酶治疗糖尿病肾病高凝状态探讨 作者 作者单位 赵长英 泸州医学院附属中医院肾病内科，四川 泸州 646000 李小军 泸州医学院附属中医院肾病内科，四川 泸州 646000 胡琼丹 泸州医学院附属中医院肾病内科，四川 泸州 646000 张茂平　　 泸州医学院附属中医院肾病内科，四川 泸州 646000 Abstract:ObjectiveTo investigate the injection of pancreatic kallikrein treatment of diabetic nephropathy(diabetic nephropathy,DN) of the efficacy and reasonable usage.Methods24 patients with diabetic nephropathy(DN group) injected after pancreatic kallikrein and 8 healthy subjects(control group) fasting blood graded elbow mining application Sonoclot analyzer and dynamic detection of enzyme-linked immunosorbent assay vein adopted Blood samples were analyzed the data again.ResultsAfter administration of 4 h,DN group all blood coagulation rate(CR) were lower than before administration,after administration 12 h,9 patients(37.5%) lower than before administration,after administration of 24 h only 6 cases(25.0%) lower than premedication.DN group of glass beads activated clotting time(gbACT) and activated partial thromboplastin time(aPrr) was positively correlated,CR and fibrinogen(FIB) was positively correlated,PF1+2 with CR was positively correlated,PF and platelet count(PLT) was positively related,GMP.No correlation between the 140 and PF.ConclusionThe injection of pancreatic kallikrein microcirculation in diabetic nephropathy there is a genuine effect,but the effective dose and effective drug delivery method also needs further study. Key words:Injection pancreatic kallikrein;Diabetic nephropathy;Sonoclot analyzer;Enzyme-linked immunosorbent assay 糖尿病肾病的病因和发病机制复杂[1]，糖尿病肾病(DN)是糖尿病的重要微血管并发症之一，其主要病理特征是肾小球内毛细血管壁增厚,血管间质区基底膜样物质沉积，最终导致肾小球硬化,出现肾功能减退甚至衰竭,是糖尿病的重要死亡原因[2-3]。患者由于长期代谢紊乱，肾小球基底膜增厚，进行性肾小球系膜扩张压迫毛细血管，在毛细血管范围内形成微循环障碍[4]。因此合理使用扩血管、改善微循环药物是治疗糖尿病肾病的重要部分。虽然目前注射用胰激肽原酶已应用于DN患者治疗，但疗效和给药方式尚无统一标准。本研究通过应用Sonoclot分析仪及酶联免疫法动态监测注射用胰激肽原酶干预前后DN患者的凝血指标，探讨注射用胰激肽原酶治疗DN的疗效及合理用法。 1 资料与方法 1.1 一般资料：选择2010年3月～8月的住院DN患者作为DN组，入选标准：①18岁以上，男女不限